Vertex Telaprevir NDA In Treatment-Naïve Hep C Now Planned For 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm expects data from pivotal 24-week trials in mid-2010.
You may also be interested in...
Vertex Kicks Off Telaprevir Pivotal Trial Next Month
Abbreviated 24-week HCV therapy regimen with telaprevir could also prove itself in vast population of treatment non-responders, company says.
Vertex Kicks Off Telaprevir Pivotal Trial Next Month
Abbreviated 24-week HCV therapy regimen with telaprevir could also prove itself in vast population of treatment non-responders, company says.
HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events
Lower 900 mcg dose of albinterferon alfa-2b is on track for hepatitis C filing in fall 2009, Human Genome Sciences says.